Making the Case for the Accelerated Withdrawal of Aducanumab
Journal of Alzheimer's Disease, ISSN: 1875-8908, Vol: 87, Issue: 3, Page: 999-1001
2022
- 12Citations
- 82Usage
- 18Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations12
- Citation Indexes12
- CrossRef12
- 11
- Usage82
- Downloads75
- Abstract Views7
- Captures18
- Readers18
- 18
- Mentions1
- News Mentions1
- News1
Most Recent News
Making the Case for the Accelerated Withdrawal of Aducanumab.
J Alzheimers Dis. 2022 Apr 23; Authors: Whitehouse PJ, Saini V PubMed: 35491796 Submit Comment
Review Description
U.S. Food and Drug Administration-s (FDA) approval of aducanumab (Aduhelm® in the US) as a treatment for mild cognitive impairment of the Alzheimer type and Alzheimer-s disease has raised such major concerns about efficacy, safety, FDA processes, and regulatory capture that Biogen-s license to market this biologic should be immediately withdrawn. Aducanumab has not demonstrated benefit to patients, failed to meet regulatory guidelines, and is likely to cause both individual and societal harm.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85131320451&origin=inward; http://dx.doi.org/10.3233/jad-220264; http://www.ncbi.nlm.nih.gov/pubmed/35491796; https://journals.sagepub.com/doi/full/10.3233/JAD-220264; https://commons.case.edu/facultyworks/59; https://commons.case.edu/cgi/viewcontent.cgi?article=1058&context=facultyworks; https://dx.doi.org/10.3233/jad-220264; https://content.iospress.com:443/articles/journal-of-alzheimers-disease/jad220264
SAGE Publications
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know